# Mark B. Faries

Source: https://onco.cc/people/mark-faries/  
OnCo record `mark-faries` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival.

## Summary

Mark Faries was principal investigator of MSLT-II, the randomised trial showing completion lymph node dissection after a positive sentinel node biopsy does not improve melanoma-specific survival, which ended routine completion dissection worldwide, and a senior investigator of MSLT-I with Donald Morton. He leads surgical aspects of neoadjuvant immunotherapy trials and the melanoma programme at the Angeles Clinic.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: melanoma; surgery; de-escalation
- Role: Co-Director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai
- Specialisms: Melanoma surgery; Sentinel node biopsy; Surgical oncology; Neoadjuvant therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Faries%20MB%5BAuthor%5D%20melanoma%20sentinel

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/)
- institutions: [Cedars-Sinai Cancer](https://onco.cc/institutions/cedars-sinai-cancer/)
- trials: [MSLT-II](https://onco.cc/trials/mslt-ii/)

---
JSON: https://onco.cc/api/v1/entities/mark-faries.json